Koba F, Tsuii H, Abe R, Asoh T, Miyazaki S, Shirasaka C, Takeuchi Y, Arinaga S, Wada T, Uchida I, Akiyoshi T, Baba T
Gan To Kagaku Ryoho. 1983 Jul;10(7):1684-90.
Patients with unresectable liver cancer (primary and metastatic) were treated with a newly-devised arterial infusion chemotherapy using Cis-DDP and its antidote Sodium thiosulfate (STS). The patients consisted of 4 with primary hepatoma and 1 with metastatic liver cancer originated from intestinal cancer. For the purpose of reducing unfavourable side effects without changing anticancer effect, Cis-DDP was infused into hepatic artery through the catheter while STS being administered systemically. According to Koyama and Saito's criteria, 2 of 5 patients showed partial response (PR) and the others showed no change (NC). The median survival time after onset of therapy was 6.6 months ranging from 2 to 11 months in all the patients. The myelosuppression and renal toxicity, which were considered to be the most serious side effects of Cis-DDP, were not found and liver function was not affected in all the patients. However, all the patients complained of nausea and vomiting. Thus, our experience has indicated that this newly devised infusion chemotherapy is a promising method for treating unresectable liver cancer, although further efforts are necessary for reducing the gastrointestinal toxicity.
无法切除的肝癌（原发性和转移性）患者接受了一种新设计的使用顺铂及其解毒剂硫代硫酸钠（STS）的动脉灌注化疗。患者包括4例原发性肝癌患者和1例源自肠道癌的转移性肝癌患者。为了在不改变抗癌效果的情况下减少不良副作用，顺铂通过导管注入肝动脉，同时全身给予硫代硫酸钠。根据小山和斋藤的标准，5例患者中有2例显示部分缓解（PR），其他患者显示无变化（NC）。所有患者治疗开始后的中位生存时间为6.6个月，范围为2至11个月。未发现被认为是顺铂最严重副作用的骨髓抑制和肾毒性，所有患者的肝功能均未受影响。然而，所有患者均抱怨有恶心和呕吐症状。因此，我们的经验表明，这种新设计的灌注化疗是治疗无法切除肝癌的一种有前景的方法，尽管还需要进一步努力来降低胃肠道毒性。
